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Abstract
Clostridium difficile infection (CDI) is one of the most common causes of nosocomial infectious diarrhea in children during
anticancer therapy or undergoing hematopoietic stem cell transplantation (HSCT) in Europe. Immunosuppression in these
patients is a risk factor for CDI. Malignant diseases, age, acute graft-versus-host disease (aGVHD), HLA mismatch, or use of
total body irradiation may play an important role in CDI course. The aim of this study was to evaluate the incidence, course, and
outcome of CDI in children treated for malignancy or undergoing HSCT. Between 2012 and 2015, a total number of 1846
patients were treated for malignancy in Polish pediatric oncological centers (PHO group) and 342 underwent transplantation
(HSCT group). In PHO group, episodes of CDI occurred in 210 patients (14%). The incidence of CDI was higher in patients with
hematological malignancies in comparison to that with solid tumors. Patients with acute myeloblastic leukemia had shorter time
to episode of CDI than those with acute lymphoblastic leukemia. Patients over 5 years and treated for acute leukemia had more
severe clinical course of disease in PHO group. In HSCT group, CDI occurred in 29 (8%) patients. The incidence of CDI was
higher in patients transplanted for acute leukemia. The recurrence rate was 14.7% in PHO and 20.7% in HSCT patients. CDI
incidence was highest in patients with hematological malignancies. Most of patients experienced mild CDI. Age < 5 years and
diagnosis other than acute leukemia were the positive prognostic factors influencing clinical CDI course.
Keywords Clostridium difficile . Malignant diseases . Pediatric hematology and oncology . Hematopoietic stem cell
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Introduction
Clostridium difficile (CD) was described for the first time in
1935. It was found in stool specimens from healthy neonates
and classified as a commensal [1], not being connected with
disease until 1978 [2, 3]. Nowadays, Clostridium difficile in-
fection (CDI) has become one of the most common causes of
nosocomial infectious diarrhea in Europe and in the USA,
resulting in a high morbidity and mortality among hospital-
ized patients. Due to common use of broad-spectrum antibi-
otics, aging of the population, and an increasing number of
severe diseases requiring healthcare interventions, problem of
CDI is growing [4–8]. The rate of CDI has doubled over the
last 10 years [9, 10]. There is a high rate of asymptomatic
colonization (14–70% in infants, 6% in children < 2 years of
age) described in healthy population [3]. C. difficile strains
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usually produce two toxins: cytotoxin B and enterotoxin—
toxin A. Sometimes binary toxin can be present, which is
connected with severe CDI course. The main symptoms of
infection are diarrhea, vomiting, abdominal pain, and fever
[11–13]. Sometimes, toxic megacolon or sepsis can occur
during CDI caused by more virulent serotypes. Traditional
risk factors for CD-associated disease are use of broad-
spectrum antibiotic, H2 blockers, chemotherapy, prolonged
immunosuppression, and long-term hospitalization [14, 15].
CD colitis is a serious complication in immunosuppressed
patients which can even end up in septicemia and a fatal out-
come [16–19]. This population needs a special attention due to
a higher incidence of the disease, presenting greater difficulty
in the interpretation of diagnostic tests because of possibility
of other causes of diarrhea. One of these groups is allogeneic
hematopoietic stem cell transplant (HSCT) recipients who re-
main at high risk for CDI, with incidence ranging from 2 to
27% [14, 15]. Numerous risk factors including acute graft-
versus-host disease (aGVHD), HLA mismatch status, intensi-
ty of conditioning, or the use of total body irradiation (TBI) in
conditioning regimens may play an important role in the
course of CDI in these patients [15, 20–23]. The aim of this
retrospective multi-center nationwide study was to determine
the incidence, clinical course, and outcome of CDI in pediatric
patients after HSCT or receiving standard chemotherapy.
Materials and methods
Patients
Between 1 January 2012 and 31 December 2015, a total num-
ber of 1846 pediatric patients were treated for malignancy and
342 HSCTs were performed in 15 Polish oncological centers.
Children were divided into two groups: patients treated with
standard chemotherapy and/or radiotherapy for hematological
malignancies or solid tumors (PHO group) and transplant re-
cipients (HSCT group). Informed consent was obtained from
parents of participants of the study.
Patients in PHO and HSCT groups were divided into three
subgroups according to primary diagnosis: group C—acute
lymphoblastic leukemia (ALL), acute myeloblastic leukemia
(AML), Hodgkin lymphoma (HL), non-Hodgkin lymphoma
(NHL), and myelodysplastic syndromes (MDS); group L—
solid tumors (ST); and group B—other (non-malignant dis-
eases, in HSCT group only).
Prophylaxis of infections
In PHO group, prophylactic trimethoprim/sulfamethoxazole
was administered in all patients starting from the day of diag-
nosis of malignancy. This prophylaxis was suspended during
treatment with methotrexate in ALL patients and during high
doses of cytarabine in AML patients. Patients with acute leu-
kemia received mold-active prophylaxis with itraconazole or
posaconazole. In the remaining low-risk cohorts, oral flucon-
azole prophylaxis was used.
All HSCT patients were followed starting from day of
transplantation up to at least 6 months post transplantation.
HSCT patients were hospitalized in single-bed rooms.
Antimicrobial prophylaxis consisted of oral ciprofloxacin
and colistin from the beginning of the conditioning regimen.
Oral or intravenous acyclovir and oral posaconazole were
started at the onset of allogenic conditioning regimen, while
fluconazole was used in autologous transplantation.
Prophylactic trimethoprim/sulfamethoxazole was given to all
patients before and after HSCT until at least 1 month after the
end of immunosuppression. Antifungal prophylaxis with
posaconazole was continued until the end of immunosuppres-
sive therapy. First-line intravenous antibiotic empiric therapy
usually included a broad-spectrum beta-lactam and
aminoglycoside.
Diagnosis of CDI
CDI was diagnosed in patients having diarrhea (more than
three semiliquid or liquid stools within 24 h) and a positive
stool test result for the presence of toxigenic C. difficile (as
detected by enzyme immunoassay, polymerase chain reaction,
or microbial culture), without evidence of another infectious
cause (rotavirus, adenovirus, Salmonella, Shigella,
Cryptosporidium) [3, 14]. Stool specimens were tested each
time in all patients having diarrhea. Additionally, asymptom-
atic HSCT patients were weekly screened for the presence of
C. difficile, rotavirus, adenovirus, and multi-resistant bacteria,
as a part of routine monitoring. Ribotyping and endoscopic
examination was not routinely performed; gastroscopy and/or
colonoscopy was done in case of suspicion of gut GVHD.
Time to CDI diagnosis in PHO group was defined as a time
from the day of beginning of oncological therapy to CDI ep-
isode, while in HSCT patients from the day of transplant to
CDI episode.
CDI recurrence was defined as a new episode of clinically
and microbiologically documented CDI separated by com-
plete resolution of clinical symptoms of primary infection
with at least 4 weeks interval.
Severe CDI course was defined by CDI first-line treatment
failure which meant lack of improvement in stool consistency
after 3 days, the need to add the second drug, new signs of
severe colitis, the need of admission to an intensive care unit,
and/or death related to CDI [17, 18].
Treatment of CDI
In case of clinical symptoms and positive A or B toxin or
binary toxin of CD before high-dose chemotherapy, treatment
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with oral metronidazole (3 × 10 mg/kg) was used for 10–
14 days. In case of busulfan-containing regimens, oral vanco-
mycin (4 × 10 mg/kg) was usually administered. In case of
severe clinical course of CDI, intravenousmetronidazole, van-
comycin, teicoplanin (10 mg/kg every 12 h for three doses,
then once daily), or oral rifaximin (3 × 200 mg) were admin-
istered, usually in combination therapy.
Statistical analysis
To compare differences between groups, the chi-square test or
Fisher exact test was used for categorical variables and the
Mann-Whitney U test for continuous variables. Hazard ratio
(HR) and 95% confidence intervals (95%CI) are shown. The
cumulative incidences of CDI were assessed using competing
risk analysis and Gray’s test. A multivariate logistic regression
using the stepwise model selection method was used to eval-
uate potential risk factors that might influence donor outcome
variables. The following risk factors were analyzed in PHO
group: age, primary diagnosis, time from diagnosis to CDI,
and duration of treatment. The following risk factors were
analyzed in HSCT group: age, primary diagnosis, time from
diagnosis to CDI, duration of treatment, type of transplant
(allo vs auto), HLA match, intensity of conditioning
(myeloablative vs others), the use of TBI, source of graft
(bone marrow vs peripheral blood), and GVHD. P < 0.05
was regarded as significant.
Results
Demographics
PHO group (n = 1846) included 386 children with ALL, 74
with AML, 114 with NHL, 108 with HL, and 1105 with ST,
and 59 were diagnosed with other diseases. HSCT group in-
cluded 342 transplants (267 allogenic and 75 autologous).
Children were transplanted due to ALL (n = 86), AML (n =
51), NHL/HL (n = 23), severe aplastic anemia (SAA) and oth-
er bone marrow failure syndromes (n = 53), ST (n = 62), PID
(n = 36), or other diseases (n = 31).
Incidence of CDI
The overall time-dependent cumulative incidence of CDI was
comparable in PHO and HSCT patients (11.8 ± 0.8% vs 8.5 ±
1.5%) (Fig. 1a). In PHO group, CDI were observed in 210
(14%) patients, including 106 boys and 104 girls (median age
6.5 years; range 0.12–18). The incidence of CDI in PHO
group reached 21% for ALL, 19% for AML, 17% for NHL,
and 11% for HL (Table 1). In ST group, the highest incidence
occurred in Ewing sarcoma (ES; 20%), followed by neuro-
blastoma (NBL; 9%), rhabdomyosarcoma (RMS; 8%), and
Wilms tumor (WT; 6%). The risk of CDI was higher in group
C than in group L (18.5 vs 7.6%; HR = 2.8, 95%CI = 2.0–3.7;
P < 0.0001) (Fig. 1b).
In HSCT group, episodes of CDI were diagnosed in 29
(8%) patients, including 24 (8.9%) in allo-HSCT recipients
and 5 (6.7%) in children after auto-HSCT (Fig. 1c). Twenty-
one out of 29 children were diagnosed with hematological
malignancies. Themedian age of patients was 9.3 years (range
2.5–19.0). The incidence was 14% for ALL, 12% for AML,
13% for lymphomas, 6% for MDS, and 5% for SAA. The
highest incidence among ST patients was 8% for ES and 6%
for NBL. The incidence of CDI was highest in group C in
comparison to that in group L and group B (Fig. 1d). The
incidence was higher in group C vs that in other patients
(HR = 3.3; 95%CI = 1.4–7.9; P = 0.005), as well as in patients
with malignant diseases vs non-malignant ones (4.2;
95%CI = 1.2–14; P = 0.01). Majority (24/29) of infected pa-
tients underwent myeloablative conditioning. In allogeneic
setting, 21/24 patients underwent matched unrelated donor
(MUD-HSCT), 2/24 had matched sibling donor (MSD-
HSCT), and one patient was given a haploidentical transplan-
tation. Bone marrow and peripheral blood were the transplant
source in 7/24 and 17/24 allo-HSCT patients with CDI,
respectively.
Clinical course/manifestation of CDI
The main symptoms in PHO group were diarrhea and fever.
The median time to develop CDI in all groups was 6.3 months
from the diagnosis of the malignancy and beginning of anti-
cancer therapy. CDI occurred earlier in group C than in group
L patients (2.6 vs 5.5 months; P < 0.001).
The median time to the CDI was shorter in AML pa-
tients than in ALL patients (1.9 vs 3.4 months, P = 0.059).
Median time of CDI treatment was 12 days (range 7–
203 days). Anti-CDI treatment was successful in first-
line therapy with metronidazole (138/159; 86.8%), vanco-
mycin or teicoplanin (28/28; 100%), and rifaximin (4/5;
80%). The success rate in second-line treatment was
100% for vancomycin (13/13), rifaximin (8/8), and met-
ronidazole (1/1). Nine patients were not given any medi-
cations, and data were not available in nine patients.
Several patients were given intravenous immunoglobu-
lins. Probiotics were used rarely due to neutropenia, and
no fecal microbiota transplantation (FMT) was performed
among PHO patients during the period of the study.
In patients after HSCT, the median time to develop
CDI was 21 days (range 2–180 days) after HSCT. CDI
occurred in 82.8% of cases during the first month after
transplantation. The median time of treatment of CDI
among HSCT recipients was 12 days (range 7–98 days),
and it was the same as in PHO group. Treatment was
successful in first-line therapy with metronidazole (13/
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24; 54.2%), vancomycin (1/2), and rifaximin (2/3). The
second-line treatment was successful in 92.3% cases after
the use of vancomycin (6/7) and rifaximin (5/5) or met-
ronidazole (1/1). In HSCT group, probiotics were used
rarely and FMT was not performed during the period of
the study. In case of hipogammaglobulinemia (< 5 g/L),
the majority of patients received immunoglobulin
supplementation.
The results of first-line treatment of CDI were better
in PHO vs those in HSCT patients (88.5 vs 55.2%;
HR = 6.3; 95%CI = 2.6–14; P < 0.0001). The efficacy of
metronidazole in first-line treatment of CDI was higher
in PHO vs that in HSCT (86.8 vs 54.2%; HR = 5.5;
95%CI = 2.2–14; P < 0.0001).
Clinically and microbiologically documented CDI re-
currences were observed in 31/210 (14.8%) PHO and in
6/29 (20.7%) HSCT patients (HR = 0.6; 95%CI = 0.3–
1.7; P = 0.8). One case of death with concomitant CDI
was reported, in 17-year-old boy with SAA (MUD,
HLA 10/10) with no signs of aGVHD. The primary
cause of death in these cases was a generalized inflam-
matory response syndrome with multi-organ failure.
Fig. 1 Cumulative incidence of infection with Clostridium difficile in: (a) PHO vs HSCT patients; (b) PHO patients group C vs group L; (c) allo-HSCT
vs auto-HSCT patients; (d) HSCT patients group C vs group L vs group B. CDI occurring after 10 months are shown on the graphs at that time point
Table 1 Frequency of CDI in
PHO and HSCT patients with
respect to primary diagnosis
PHO HSCT HR (95%CI) P
Acute lymphoblastic leukemia 81/386 (21.0%) 12/86 (13.9%) 1.6 (0.8–3.1) 0.13
Acute myeloblastic leukemia 14/74 (18.9%) 6/51 (11.8%) 1.7 (0.6–4.9) 0.28
Non-Hodgkin lymphoma 19/114 (16.7%) 2/13 (15.4%) 1.1 (0.2–5.5) 0.90
Hodgkin lymphoma 12/108 (11.1%) 1/10 (10.0%) 1.1 (0.2–9.6) 0.91
Solid tumors 84/1105 (7.6%) 4/62 (6.5%) 1.2 (0.4–3.3) 0.74
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Multivariate analysis for clinical severity of CDI
In multivariate analysis (Table 2) in PHO group, patients under
5 years had milder course of disease (HR = 1.8; P = 0.048).
Patients with diagnosis of acute leukemia had clinically more
severe disease (HR = 3.1; P = 0.036). There was no significant
impact of sex, time to CDI, and duration of treatment. Among
children who underwent HSCT, no factor contributed to sever-
ity of disease and outcome, although there was a trend towards
more severe clinical course of CDI in patients treated for acute
leukemia or older than 5 years (Table 2).
Discussion
Patients at high risk of CDI include solid organ or hematopoietic
transplant recipients. The incidence of CDI inHSCTgroup varies
between 2 and 27% [14, 15]. Some variations between studies
might depend on cohort size and percentage of autologous recip-
ients [24]. Patients after HSCT had CDI cumulative incidence of
13% at 1 year, with 50% of infections occurring during the first
month after HSCT. Boyle et al. found that 11% of adults and
17% of children developed episode of CDI by day + 100 [25].
In our study, we observed incidence of 8.5% among HSCT
recipients, including 8.9% allo-HSCT and 6.7% auto-HSCT.
In PHO group, the incidence was 14% among all patients with
malignancy. Higher rate of CDI in allogeneic HSCT recipients
can occur due to a higher incidence of the main risk factors for
CDI such as prolonged hospitalization, gastrointestinal muco-
sa damage due to chemotherapy, radiotherapy, frequent use of
antibiotics, and development of gastrointestinal GVHD [26].
The type of malignancy can also influence a predisposition for
CDI; however up to now, no clear relationship between the
type of cancer and the risk of CDI has been described [27]. In
our study, we observed a higher incidence of CDI in children
with hematological malignancies both in PHO group and in
patients after transplantation.
Another important risk factor is age. Among pediatric pa-
tients, the risk of CDI varies by age, as older children are
regarded to have a lower rate of CDI [28–30]. Neonates and
infants who are at high risk of asymptomatic carriage of C.
difficilemay serve as a reservoir for infection. Exposure to other
children and fomites (e.g., toys) may facilitate with transmis-
sion of C. difficile and play an important role in this population.
According to our observation, severe clinical course of CDI
occurred more often in older group: in PHO group, we ob-
served that younger patients (< 5 years) had milder course of
disease. Similar trend was found among HSCT recipients.
We did not find HLA matching status, intensity of condi-
tioning, use of TBI, or GVHD to be a significant risk factor for
a longer period of treatment or more severe CDI course, as
some authors reported [20, 21, 23]. In a case-control study of
37 allogeneic HSCT recipients with CDI, Dubberke et al. [31]
found an increased risk of GVHD, severe GVHD, and gut
GVHD after CDI. In multivariate analysis, they observed that
aGVHD and the use of cord blood as the source of stem cells
were identified as risk factors for CDI. Chakrabarti et al. [20]
also described aGVHD grades 3 to 4 to be a risk factor for
CDI, and that study was the first to report the use of cord blood
as a risk factor for CDI. Relationship between CDI and
GVHD still remains a complex issue. CDI may increase the
risk of GVHD during the first year after infection, what can
suggest that microbial antigenicity and/or the patient response
to the infection may contribute to the pathogenesis of GVHD
[24]. Boyle et al. found that overall gastrointestinal GVHD
significantly predicted the development of CDI between
2 months and 1 year after transplant [25].
The main manifestations of CDI infection are diarrhea and
abdominal pain which can also be found in patients with other
infections such as adenovirus, norovirus, Salmonella, E. coli,
norovirus, and colitis ulcerosa and in patients suffering from
inflammatory diseases or receiving anti-inflammatory (e.g., ste-
roids) or antiviral drugs [14, 32]. Chakrabarti et al. found that
frequent co-infections which cause abdominal pain, fever, or
diarrhea may mislead to an overestimation of the rate of CDI.
On the other hand, it is also true that patients with asymptomatic
colonization can progress to symptomatic infection [20].
Treatment algorithm for CDI in hematological patients de-
pends on the severity of infection. Metronidazole remains still
the “gold standard” in treatment of CDI. Due to the intoler-
ance or in case of recurrent infection (frequent presence of
metallic taste, mucositis, and nausea in patients treated with
metronidazole), some authors recommend to use vancomycin.
For patients with complicated CDI with ileus or toxic colitis
and/or significant abdominal distention, vancomycin deliv-
ered orally (500 mg four times per day) and/or per rectum
(500 mg in a volume of 500 mL four times a day) plus intra-
venous metronidazole (500 mg three times a day) is the
Table 2 Multivariate logistic
regression analysis for risk factors
of severe clinical course of CDI
PHO* HSCT*
HR (95%CI) P HR (95%CI) P
Diagnosis of acute leukemia 3.1 (1.1–8.6) 0.036 1.4 (0.98–2.1) 0.076
Age > 5 years 1.8 (1.0–5.2) 0.048 1.6 (0.8–6.3) 0.097
*All other factors were not significant
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treatment of choice. Supportive care including intravenous
fluid resuscitation and electrolyte replacement should be de-
livered to all patients with severe CDI. In the absence of sig-
nificant abdominal distention or ileus, oral or enteral feeding
should be continued [33, 34]. In case of neutropenia and pos-
sibility of sepsis in immunocompromised patients, probiotics
should be used with caution [35, 36]. Nowadays, new antibi-
otics including surotomycin, cadazolid, and ridinilazol have
been developed for the treatment of CDI. Recent clinical stud-
ies demonstrated bezlotoxumab (anti-CD toxin B monoclonal
antibodies) to be a valuable therapeutic option [37, 38].
Metronidazole was the first choice in our study population.
In severe cases, we used vancomycin in monotherapy, or to-
gether with metronidazole in combination therapy. In some
cases, we administered also rifaximin or teicoplanin with very
good efficacy. The clinical presentation of CDI in pediatric
patients in most cases presented as mild-to-moderate diarrhea,
abdominal pain, and vomiting. Severe complications of CDI,
such as fulminant CDI or pseudomembranous colitis, are not
common among children [16–18]. Neither Antonara et al. [17]
nor Chakrabarti et al. observed severe CDI or death attributing
to CDI [20]. Contrary, in the other study of 37 patients, the
increased risk of death was evaluated at 180 days and restrict-
ed to patients with severe CDI (57% of patients) [39]. Raising
incidence of CDI associated with the emergence of more vir-
ulent strains since 2002 raises new concerns regarding the
impact on mortality, especially in immunocompromised pa-
tients [20]. In our study, most of patients experienced relative-
ly mild CDI with good response to antibiotic therapy.
Conclusions
CDI occurred in 14% PHO and 8.5% HSCT patients, includ-
ing 6.7% patients after autologous HSCT. The highest inci-
dence occurred in patients with hematological malignancies
both after transplantation and during conventional chemother-
apy. Children with AML have shorter time to CDI than pa-
tients with ALL; however, most of patients experienced rela-
tively mild clinical course with adequate response to antibiotic
therapy. We confirm metronidazole to be the first choice op-
tion in CDI treatment in PHO patients. Almost all children
responded well to the treatment with limited adverse effects,
observed only in a few patients. CDI rarely contributed to
death among children during conventional oncological treat-
ment or in transplant recipients. In non-HSCT children, youn-
ger age (< 5 years) and diagnosis other than acute leukemia
were the prognostic factors for less severe clinical CDI course.
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